AZ-WORLD-VIEW
31.3.2022 17:02:13 CEST | Business Wire | Press release
World View , the leading stratospheric ballooning and space tourism company, today announced environmentalist, actor, and UN Environment Goodwill Ambassador Adrian Grenier has been named its Chief Earth Advocate. In this new role he will support World View’s mission to rediscover Earth, inspiring new perspectives on the planet and encouraging deeper respect for it as a living organism. Today’s announcement follows the company’s entry into the space tourism and exploration market offering an affordable, long duration and accessible space experience on Earth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005341/en/
World View designed its space tourism experience based on the company’s business purpose: World View exists to inspire, create, and explore new perspectives for a radically improved future. The company believes its space tourism experience provides customers with an “awe inspiring” journey, from the time spent at one of World View’s spaceports to the time spent at the edge of space. World View is on a mission to deliver this transformative moment to a critical mass of humans knowing that it could lead to a markedly improved future for our fragile planet.
In his new role, Grenier will collaborate with World View’s leadership to ideate and develop strategies to ensure the company's sustainability goals are met through global partnerships, programming, and initiatives. He will also contribute to the development of its environmental strategy while playing a key role in helping participants understand their individual relationship to the planet as they prepare for and reflect on their trip.
"Adrian’s history as an eco-activist speaks for itself. World View is happy to welcome Adrian as our Chief Earth Advocate. Our main goal is to enable customers to see the beauty of the Earth we inhabit so we can radically improve the future of our own planet. Adrian is an excellent advocate and will help us in our mission,” said Ryan Hartman, President and CEO of World View.
Conservation has long been at the heart of Grenier’s social activism. In 2017, he helped the UN Environment Programme launch Clean Seas, a campaign to end marine plastic pollution. He also supported Wild for Life, advocating for the conservation of sawfish. The Lonely Whale Foundation, which he co-founded, strives to inspire empathy towards marine species and develop lifelong advocates for ocean health. Its innovative StopSucking campaign aims to discourage the use of single-use plastic straws, which are particularly harmful to marine wildlife. Grenier actively supports organizations focused on habit-changing education.
“I am honored to serve as World View’s Chief Earth Advocate. The partnership allows me to use my platform to champion healthier, regenerative choices for the Earth. Space tourism is an exciting concept, and the fact that World View puts our interconnectedness squarely at the heart of exploration is in line with my personal values. Together, we will be able to honor the planet and encourage future generations to be better stewards of its resources and beauty,” said Adrian Grenier, Chief Earth Advocate of World View.
World View Mission: Rediscover Earth
World View’s global space tourism program will begin its first commercial flights in early 2024. Unlike any other space tourism company, World View plans to have flights depart from state-of-the-art spaceports located in iconic locations like the Grand Canyon and Great Barrier Reef, providing participants the opportunity to experience natural and man-made wonders from the ground and the edge of space.
Flights will lift eight participants and two World View crew members in a zero-pressure stratospheric balloon and pressurized space capsule to 100,000 feet altitude, nearly 23 miles into the stratosphere, for a life-changing experience that will last six to 12 hours with average flight duration between six and eight hours. Participants will lift off before dawn to watch the sunrise over Earth, view the curvature of our planet and experience the darkness of space. They will see a world without borders, without race and will fully experience and immerse themselves in the beauty, fragility, history, and importance of the areas surrounding each location and of the Earth itself.
ABOUT WORLD VIEW
World View is the leading stratospheric exploration company on a mission to inspire the global community to rediscover Earth. Through both its legacy Stratollite imaging and newly launched space tourism and exploration businesses, World View is working to ensure its ultimate objective: honor the planet so that future generations will feel blessed to call it home. For more information, visit worldview.space .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005341/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
